Cargando…
Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective
Chimeric antigen receptor T (CAR T)-cell therapy promises to revolutionize the management of hematologic malignancies and possibly other tumors. However, the main side effect of cytokine release syndrome (CRS) is a great challenge for its clinical application. Currently, treatment of CRS caused by C...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009180/ https://www.ncbi.nlm.nih.gov/pubmed/36923358 http://dx.doi.org/10.3389/fphar.2023.1134174 |